FDA Considers BLA for Pertuzumab Biosimilar HLX11 in Breast Cancer
The FDA accepted for review a biologics license application (BLA) seeking the approval of HLX11 for the treatment of select patients with HER2-positive breast cancer. HLX11 is an investigational biosimilar referencing pertuzumab (Perjeta). Data from a …